Gal-3 blocks the binding between PD-1 and pembrolizumab
Stinne Ravn Greisen(Aarhus University), Bent Deleuran(Aarhus University), Morten Aagaard Nielsen(Aarhus University Hospital), Mia Bendix(Aarhus University Hospital), Malene Hvid(Aarhus University), Torben Steiniche(Aarhus University), Henrik Schmidt(Aarhus University Hospital), Jakob Hauge Mikkelsen(Aarhus University), Thomas Boesen(Aarhus University), Nina Haunstrup Jensen(Aarhus University), Taner Drace(Aarhus University), Kathrine Pedersen(Aarhus University)
Cited by 11
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2015|1.3k
Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders
|PEDIATRICS|2009|409
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|386